60. 再生不良性貧血 Aplastic anemia Clinical trials / Disease details

臨床試験数 : 235 / 薬物数 : 381 - (DrugBank : 83) / 標的遺伝子数 : 44 - 標的パスウェイ数 : 160

3 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04328727 (ClinicalTrials.gov)	November 4, 2020	9/3/2020	Combination of Eltrombopag With Immunosuppressive Therapy in East-Asian Patients With Severe Aplastic Anemia	A Non-randomized, Open Label, Multi-center, Phase II Study to Assess the Safety and Efficacy of Eltrombopag in Combination With Rabbit Anti-thymocyte Globulin (r-ATG) and Cyclosporine A (CsA) in East-Asian Patients With Treatment Naive Severe Aplastic Anemia (REACTS)	Severe Aplastic Anemia (SAA)	Drug: eltrombopag;Drug: rabbit anti-thymocyte globulin (r-ATG);Drug: cyclosporine A (CsA)	Novartis Pharmaceuticals	NULL	Active, not recruiting	6 Years	N/A	All	36	Phase 2	China;Japan;Korea, Republic of;Taiwan
2	NCT01231841 (ClinicalTrials.gov)	March 2005	29/10/2010	Anti-thymocyte Globulin and Cyclosporine as First-Line Therapy in Treating Patients With Severe Aplastic Anemia	Protocol for Prospective Phase II Study of Rabbit Antithymocyte Globulin (r-ATG/Thymoglobulin) and Cyclosporine (CsA) as a First Line Immunosuppressive (IS) Therapy for Severe Aplastic Anemia (sAA)	Aplastic Anemia	Drug: cyclosporine;Biological: anti-thymocyte globulin	The Cleveland Clinic	NULL	Completed	12 Years	N/A	All	20	Phase 2	United States
3	NCT00065260 (ClinicalTrials.gov)	July 2003	18/7/2003	Rabbit Antithymocyte Globulin Versus Campath-1H for Treating Severe Aplastic Anemia	A Randomized Trial of Immunosuppression in Aplastic Anemia Patients With Refractory Pancytopenia or Suboptimal Hematologic Response After h-ATG/CsA Treatment	Aplastic Anemia	Drug: Campath -1H;Drug: r-ATG;Drug: CsA	National Heart, Lung, and Blood Institute (NHLBI)	NULL	Completed	2 Years	N/A	All	54	Phase 2	United States